Bank of America Analyst Bullish on 4D Molecular Therapeutics' 4D-150 Treatment for Diabetic Macular Edema

4D Molecular Therapeutics' 4D-150 treatment for diabetic macular edema has shown promising clinical data with sustained efficacy and a favorable safety profile. Analyst Daniel Giraldo from Bank of America Securities maintains a Buy rating and a $30 price target, expecting the therapy to capture a significant share of the evolving treatment landscape. Giraldo is optimistic about the long-term durability and reduced treatment burden of 4D-150, which could be used in 20-30% of DME patients.

4D Molecular Therapeutics (FDMT) has announced significant milestones in its clinical trials for the 4D-150 treatment for diabetic macular edema (DME). The company presented interim results from the SPECTRA Phase 2a trial at the 43rd Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) in Long Beach, CA, from July 30 to August 2, 2025. The presentation highlighted 52-week and 60-week data, showcasing the sustained efficacy and favorable safety profile of 4D-150 [1].

The SPECTRA trial, led by Dr. David Almeida, focused on the use of 4D-150 for DME. The data presented at the ASRS meeting demonstrated the therapy's ability to provide long-term benefits to patients with DME, potentially reducing the treatment burden associated with current bolus injections. The company also presented results from the PRISM Phase 2b trial evaluating 4D-150 for neovascular age-related macular degeneration (nAMD) on August 1, 2025 [1].

Analyst Daniel Giraldo from Bank of America Securities maintains a Buy rating for FDMT and has set a $30 price target on the stock. Giraldo is optimistic about the long-term durability and reduced treatment burden of 4D-150, expecting the therapy to capture a significant share of the evolving treatment landscape for DME. He estimates that 4D-150 could be used in 20-30% of DME patients [2].

4D Molecular Therapeutics is a leading late-stage biotechnology company specializing in disease-targeted therapeutics. The company's lead product candidate, 4D-150, is designed to be a backbone therapy for blinding retinal vascular diseases, providing multi-year sustained delivery of anti-VEGF with a single, safe, intravitreal injection. The company's second product candidate, 4D-710, is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery [2].

The presentations at the ASRS meeting highlighted the company's commitment to advancing innovative treatments for retinal diseases. The successful presentation of data at the Annual Scientific Meeting of the American Society of Retina Specialists positions the company favorably for attracting attention from investors and the medical community.

References:
[1] https://www.nasdaq.com/articles/4d-molecular-therapeutics-announces-presentations-asrs-2025-phase-2-clinical-trials-4d-150
[2] https://finimize.com/content/fdmt-asset-snapshot